Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared an updates from AACR25 on X:
“Exciting update from AACR25!
Combo of Botensilimab + Balstilimab in neoadjuvant setting:
pMMR tumors: 70% MPR
dMMR tumors: 80% MPR, 70% pCR
Low-grade irAEs and no surgical delays!
Organ preservation possible
High response even in ‘cold’ tumors like UPS, ER+BC, TNBC!
Promising step for neoadjuvant immunotherapy”
BIG NEWS at AACR25
“Aumolertinib + Chemo for metastatic EGFR+ NSCLC!
Median PFS: 28.9 vs 18.9 months (HR 0.47)
Early OS trend: HR 0.44
Strong across all subgroups — gender, CNS mets, EGFR mutations
Especially powerful in young, smokers, Ex19del patients!
CNS control preserved!
Compared to Osimertinib+Chemo (FLAURA2):
Higher PFS
Better HRs across key groups
Could Aumolertinib + Chemo redefine EGFR NSCLC management? Or another Me Too combination?
Time will tell!
We need more global data and off course toxicity data”
More posts featuring AACR25
